WO2006134280A3 - Sequences nucleotidiques mutees du virus de l'hepatite c - Google Patents

Sequences nucleotidiques mutees du virus de l'hepatite c Download PDF

Info

Publication number
WO2006134280A3
WO2006134280A3 PCT/FR2006/001370 FR2006001370W WO2006134280A3 WO 2006134280 A3 WO2006134280 A3 WO 2006134280A3 FR 2006001370 W FR2006001370 W FR 2006001370W WO 2006134280 A3 WO2006134280 A3 WO 2006134280A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
hepatitis
virus
nucleotide sequence
mutated nucleotide
Prior art date
Application number
PCT/FR2006/001370
Other languages
English (en)
Other versions
WO2006134280A2 (fr
Inventor
Genevieve Inchauspe
Christine Bain
Anne Fournillier
Marc Fiorucci
Original Assignee
Transgene
Centre Nat Rech Scient
Genevieve Inchauspe
Christine Bain
Anne Fournillier
Marc Fiorucci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0506170A external-priority patent/FR2887260A1/fr
Application filed by Transgene, Centre Nat Rech Scient, Genevieve Inchauspe, Christine Bain, Anne Fournillier, Marc Fiorucci filed Critical Transgene
Publication of WO2006134280A2 publication Critical patent/WO2006134280A2/fr
Publication of WO2006134280A3 publication Critical patent/WO2006134280A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention a pour objet l'utilisation d'une séquence nucléotidique mutée, cette séquence mutée étant dérivée par mutation d'une séquence nucléotidique codant pour une protéine comprenant ou constituée par la protéine Core ou un fragment de la protéine Core, et le cas échéant la protéine El et / ou la protéine E2 du virus de l'hépatite C et / ou un ou des fragments de la protéine El et / ou de la protéine E2 du virus de l'hépatite C, ladite séquence nucléotidique mutée étant telle qu'elle code dans un cadre de lecture 0 pour la susdite protéine, mais qu'elle ne permet pas l'expression d'une protéine ARFP ou de fragments d'une protéine ARPP de plus de 11 acides aminés, codés dans le cadre de lecture +1 par la susdite séquence nucléotidique non mutée, pour la préparation d'un vaccin ou d'un médicament destiné à la prévention ou au traitement des infections liées au virus de l'hépatite C.
PCT/FR2006/001370 2005-06-17 2006-06-16 Sequences nucleotidiques mutees du virus de l'hepatite c WO2006134280A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0506170A FR2887260A1 (fr) 2005-06-17 2005-06-17 Sequences nucleotidiques mutees du virus de l'hepatite c
FR0506170 2005-06-17
US76036406P 2006-01-20 2006-01-20
US60/760,364 2006-01-20

Publications (2)

Publication Number Publication Date
WO2006134280A2 WO2006134280A2 (fr) 2006-12-21
WO2006134280A3 true WO2006134280A3 (fr) 2007-02-22

Family

ID=37102180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001370 WO2006134280A2 (fr) 2005-06-17 2006-06-16 Sequences nucleotidiques mutees du virus de l'hepatite c

Country Status (1)

Country Link
WO (1) WO2006134280A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685944B1 (en) * 1998-08-21 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Modified HCV peptide vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685944B1 (en) * 1998-08-21 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Modified HCV peptide vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARIL MARTIN ET AL: "Translation of the F protein of hepatitis C virus is initiated at a non-AUG codon in a+1 reading frame relative to the polyprotein", NUCLEIC ACIDS RESEARCH, vol. 33, no. 5, 8 March 2005 (2005-03-08), pages 1474 - 1486, XP002370818, ISSN: 0305-1048 *
BRANCH ANDREA D ET AL: "The hepatitis C virus alternate reading frame (ARF) and its family of novel products: The alternate reading frame protein/F-protein, the double-frameshift protein, and others", SEMINARS IN LIVER DISEASE, vol. 25, no. 1, February 2005 (2005-02-01), pages 105 - 117, XP009062779, ISSN: 0272-8087 *

Also Published As

Publication number Publication date
WO2006134280A2 (fr) 2006-12-21

Similar Documents

Publication Publication Date Title
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
CY1117351T1 (el) Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
CA2856891C (fr) Acide nucleique comprenant ou codant pour une tige-boucle d'histone et une sequence poly(a) ou un signal de polyadenylation pour augmenter l'expression d'un antigene pathogene cod e
WO2009124312A3 (fr) Séquences consensus de protéines du virus chikungunya, molécules d’acide nucléique codant pour celles-ci, et compositions et procédés d’utilisation de celles-ci
NZ598351A (en) Il-17 binding compounds and medical uses thereof
UA98620C2 (uk) Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2
TW200716671A (en) Improved nanobodies against tumor necrosis factor-alpha
JP2008508859A5 (fr)
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
EA201100071A1 (ru) Новые композиции и способы
WO2007050095A3 (fr) Vaccins améliorés et leurs procédés d'utilisation
MXPA05005202A (es) Vacuna.
WO2008087224A3 (fr) Netrine 4 mutée, fragments de cette dernière et utilisations comme médicament
WO2009025300A1 (fr) Peptide capable de se lier à une immunoglobuline
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2010103515A3 (fr) Compositions et procédés pour la prévention et le traitement de maladies neurodégénératives
WO2008027560A3 (fr) Vaccins et réactifs renforcés à la holine et procédés d'utilisation correspondants
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
DK1913020T3 (da) Immunogene konstrukter
WO2006134280A3 (fr) Sequences nucleotidiques mutees du virus de l'hepatite c
WO2004074491A3 (fr) Expression dans des plantes d'anticorps contre l'escherichia coli entero-toxigene
TW200801034A (en) Novel sea lice vaccine
WO2005056051A3 (fr) Vaccins contre l'hepatite b et leurs compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06778607

Country of ref document: EP

Kind code of ref document: A2